IMMX
Immix Biopharma Inc.
$3.80
+$0.13(+3.54%)
64
Overall
60
Value
100
Tech
34
Quality
Market Cap
$56.46M
Volume
1.62M
52W Range
$1.34 - $4.05
Target Price
$8.00
Order:
Income Statement
| Metric | Trend | Chart | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|
| OPERATING EXPENSES | ||||||
| Operating Expenses | $1.4M | $8.2M | $16.1M | $22.7M | ||
| Research & Development | $126.5K | $4.2M | $8.7M | $11.3M | ||
| Research Expense | $126.5K | $4.2M | $8.7M | $11.3M | ||
| Selling, General & Administrative | $1.2M | $4.0M | $7.4M | $11.4M | ||
| General & Administrative Expenses | $1.2M | $4.0M | $7.4M | $11.4M | ||
| Salaries & Wages | $-160.0K | -- | $2.6M | $3.0M | ||
| Depreciation & Amortization | -- | -- | $5.5K | $32.9K | ||
| Depreciation & Amortization | -- | -- | $5.5K | $32.9K | ||
| Amortization | $-58.2K | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | $225.2K | ||
| OPERATING INCOME | ||||||
| Operating income | $-1.4M | $-8.2M | $-16.1M | $-22.7M | ||
| EBITDA | $-24.1M | $-8.2M | $-15.6M | $-21.5M | ||
| NON-OPERATING ITEMS | ||||||
| Interest Expense (Non-Operating) | $179.9K | $497 | -- | -- | ||
| Intinc | -- | -- | $572.0K | $1.0M | ||
| Net Non-Operating Interest Income/Expense | $-179.9K | $-497 | $572.0K | $1.0M | ||
| Other Income/Expense | $22.8M | -- | -- | -- | ||
| Other Special Charges | $-86.2K | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||
| EBIT | $-24.2M | $-8.2M | $-15.6M | $-21.7M | ||
| Pre-Tax Income | $-24.4M | $-8.2M | $-15.6M | $-21.7M | ||
| INCOME TAX | ||||||
| Tax Provision | $6.0K | $10.3K | $26.4K | $41.0K | ||
| NET INCOME | ||||||
| Net Income | $-24.4M | $-8.2M | $-15.4M | $-21.6M | ||
| Net Income (Continuing Operations) | $-24.4M | $-8.2M | $-15.6M | $-21.7M | ||
| Net Income (Discontinued Operations) | $-24.4M | $-8.2M | $-15.4M | $-21.6M | ||
| Net Income (Common Stockholders) | $-24.4M | $-8.2M | $-15.4M | $-21.6M | ||
| Normalized Income | -- | -- | -- | $-21.4M | ||
| TOTALS | ||||||
| Total Expenses | $1.4M | $8.2M | $16.1M | $22.7M | ||
| SHARE & EPS DATA | ||||||
| Average Shares Outstanding | $3.7M | $13.9M | $17.3M | $28.3M | ||
| Average Shares Outstanding (Diluted) | $3.7M | $13.9M | $17.3M | $28.3M | ||
| Shares Outstanding | $13.9M | $13.9M | $26.4M | $27.7M | ||
| Basic EPS | -- | $-0.59 | $-0.89 | $-0.76 | ||
| Basic EPS (Continuing Operations) | -- | $-0.59 | $-0.89 | $-0.76 | ||
| Diluted EPS | $-6.64 | $-0.59 | $-0.89 | $-0.76 | ||
| Diluted EPS (Continuing Operations) | $-6.64 | -- | $-0.89 | $-0.76 | ||
| OTHER METRICS | ||||||
| Acquired In Process Rn D Income | $-22.8M | -- | -- | -- | ||
| Minority Interests | -- | -- | $169.5K | $85.0K | ||
| Other Gand A | $1.2M | $4.0M | $7.4M | $11.4M | ||
| Realized Capital Gain | $-22.8M | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | IMMX | $3.80 | +3.5% | 1.62M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |